Literature DB >> 31896913

Role of plasma exchange in postpartum microangiopathies: An experience from a tertiary care center.

Rekha Hans1, Satya Prakash1, Divjot Singh Lamba1, Ratti Ram Sharma1, Pankaj Malhotra2, Vanita Suri3, Neelam Marwaha1.   

Abstract

BACKGROUND: Postpartum microangiopathies are rare but are associated with high maternal and fetal mortality requiring early diagnosis and prompt treatment to improve the outcome. AIMS AND
OBJECTIVES: This retrospective study aims to assess the efficacy of plasma exchange (PE) therapy in postpartum thrombotic microangiopathies.
MATERIALS AND METHODS: We did retrospective analysis of all plasma exchange procedures performed in patients of postpartum thrombotic microangiopathies over a period of 1 year (2015-2016). Patient's pre- and post-plasma exchange hematological and biochemical parameters were recorded and compared for analyzing the response to the therapy. Patients were followed telephonically even after their discharge from the hospital.
RESULTS: Hematological and renal profile improved in 8 out of 9 patients after PE therapy. Survival after PE therapy was 40% in post partum atypical HUS and 75% in patients with HELLP syndrome at 4 months of follow up.
CONCLUSION: Early initiation of PE therapy in postpartum thrombotic microangiopathies can reduce morbidity and mortality associated with them. Copyright:
© 2019 Asian Journal of Transfusion Science.

Entities:  

Keywords:  Microangiopathy; plasma exchange; postpartum

Year:  2019        PMID: 31896913      PMCID: PMC6910027          DOI: 10.4103/ajts.AJTS_16_19

Source DB:  PubMed          Journal:  Asian J Transfus Sci        ISSN: 0973-6247


Introduction

Plasma exchange (PE) has been successfully tried and recommended for various postpartum microangiopathies such as postpartum hemolytic uremic syndrome (HUS), thrombotic thrombocytopenic purpura (TTP), and HELLP syndrome as per the latest American Society for Apheresis (ASFA) guidelines.[1] Pregnancy being a hypercoagulable state is prone to the acute episodes of hemolytic anemia, thrombocytopenia, and acute renal failure.[2] Since laboratory profile of thrombotic microangiopathies is overlapping, hence it poses a great challenge to distinctly label the definite diagnosis in a particular patient. Furthermore, these conditions are associated with high perinatal or maternal morbidity and mortality[3] demanding early diagnosis and prompt treatment to improve the outcome. Here, we present our experience of PE in patients of postpartum HUS and HELLP syndrome referred to us from the department of Obstetrics and Gynaecology in our institute.

Materials and Methods

We did a retrospective analysis of our PE records over a period of 1 year (2015–2016) during which five cases of suspected postpartum HUS and four cases of HELLP syndrome (based on their laboratory and clinical profile) were referred to the department of Transfusion Medicine from the department of Obstetrics and Gynaecology of our tertiary care institute. These cases were referred to our institute from the peripheral regional health-care settings.

Plasma exchange intervention

PE procedures were performed on cell separator Cobe® Spectra (Terumo BCT, Lakewood, Colorado, USA) after priming the disposable kit with group-specific, crossmatched packed red blood cells due to low hemoglobin (<8 g/dl) of the patients. The replacement fluid used was fresh frozen plasma with a negative balance of 10% to prevent cardiac overload in the patients as these patients were oliguric or anuric. Procedures were done on daily (n = 3) or on alternate days (n = 6) depending on the clinical condition and hemodialysis requirements of the patients. Ionized calcium was monitored before the start of the procedure, and calcium infusion (1%) was given throughout the procedure. Preprocedure hematological, renal, and liver functions were noted, and these parameters were followed after each PE procedure for analyzing the response to the therapy. Patients were followed telephonically even after their discharge from the hospital.

Results

Patient characteristics of suspected postpartum hemolytic uremic syndrome patients

Of the five HUS patients, four were primigravida and one was multigravida. The age of patients ranged from 23 to 30 years. The details of antenatal and delivery outcome of these patients are shown in Table 1. The onset of clinical features suggestive of HUS was observed on day 2 in Cases I, II, and V and day 5 postabortion in Case III, and in Case IV, it was postpartum day 7. Patients were referred immediately to our institute with features of oliguria and thrombocytopenia.
Table 1

Clinical profile of patients suspected of postpartum hemolytic uremic syndrome

FeaturesCase ICase IICase IIICase IVCase V
Age (years)3024302723
GravidaPrimiPrimiMulti (G6P4A1L4)PrimiPrimi
Mode of deliveryTerm, Emg LSCSTerm, LSCSAbortion at 28 WeeksTerm, LSCSTerm, LSCS
Status of babyAlive and healthyAlive and healthyNAAlive and healthyAlive and healthy
Antenatal periodUneventfulUneventfulUneventfulUneventfulUneventful
Onset of clinical signs and symptoms (postpartum/postabortion)Day 2Day 2Day 5Day 7Day 2
Time between illness onset and PE4 days3 days2 days3 days2 days
Presenting clinical featuresPedal and facial edema, low urine outputlow urine output, bleeding from the urethra and ET tube, JaundiceGeneralized edema with low renal outputClinical pallor with edema over the face and legPallor, edema over the face and leg and low renal output
Hemodialysis (number of procedures)2NDND38
Length of hospital stay (days)201071419

LSCS=Lower segment caesarean section, ET=Endotracheal tube, ND=Not done, PE=Plasma exchange

Clinical profile of patients suspected of postpartum hemolytic uremic syndrome LSCS=Lower segment caesarean section, ET=Endotracheal tube, ND=Not done, PE=Plasma exchange

Response to plasma exchange therapy and outcome of suspected hemolytic uremic syndrome patients

All patients showed improvement in their hematological and renal profile after PE, as shown in Table 2. However, only two patients (Case I and Case V) survived on follow-up. One patient (Case II) showed improvement in her biochemical and renal profile; however, she left the hospital against medical advice and on telephonic follow-up found to be expired. Another patient (Case III) underwent two PE procedures, but the patient expired after the second therapeutic plasma exchange (TPE) procedure due to septicemic shock as the patient left the hospital against medical advice. Case IV improved and was discharged; however, on follow up, the patient was found to be expired in a local hospital after getting some treatment for complaints of pain abdomen 1 week after discharge from the hospital.
Table 2

Pre- and post-plasma exchange pattern of laboratory (hematological and renal) profile of the patients

Laboratory profile of suspected postpartum hemolytic uremic syndrome patients

Case/PE proceduresHematological profileRenal profileOutcome At 4 months of follow-up


Hemoglobin (g/l)Platelet count (109/L)Lactate Dehydrogenase (µkat/L)Bilirubin (mg/dl)Peripheral Blood Film (%Schistocytes)Serum urea (mmol/L)Serum creatinine (µmol/L)Urine output (ml/kg/h)








Pre-PEPost-PEPre-PEPost-PEPre-PEPost-PEPre-PEPost-PEPre-PEPost-PEPre-PEPost-PEPre-PEPost-PEPre-PEPost-PE
Case I (4)92994644047.5814.951.60.55Nil31.0618.56442530.400.11Alive
Case II (4)69768061169.3016.031.30.36Nil40.7028.56362.44335.920.10.2Expired
Case III (2)827310113820.0413.681.261.064227.4956.05238.68423.440.10.3Expired
Case IV (5)6670639671.7435.351.411.59183.1810.35689.5222111.5Expired
Case V (2)74822095822.2615.881.21.14229.2722.13309.40185.640.51Alive

PE=Plasma exchange

Pre- and post-plasma exchange pattern of laboratory (hematological and renal) profile of the patients PE=Plasma exchange

Patient characteristics of suspected HELLP syndrome

Of four patients with HELLP syndrome, two were primigravida and the other two were multigravida. The age of patients ranged from 20 to 30 years. The details of antenatal and delivery outcome of these patients are shown in Table 3. HELLP syndrome was diagnosed in three of these patients during antenatal period, and one patient had uneventful history during antenatal phase. Patients were referred to our institute with complaints of oliguria, thrombocytopenia, and elevated liver enzymes within 1–5 days of the onset of these clinical signs and symptoms.
Table 3

Clinical profile of patients suspected of HELLP

FeaturesCase ICase IICase IIICase IV
Age (years)20253028
GravidaPrimiMulti G3P2002PrimiMulti
Mode of deliveryNVD for IUFDNVD breech at homeLSCSNVD
Status of babyStillbirthAliveAliveStillbirth
Antenatal periodhypertensionuneventfulhypertension in the last trimesterhypertension
Onset of clinical signs and symptoms (postpartum/postabortion)Day 1Day 5Day 5Day 1
Time between illness onset and PE6 days0 day2 days7 days
Presenting clinical featuresOliguria, facial and pedal edemaOliguria, facial and pedal edemaAscites, anuria, pedal edemaIncreased bilirubin, swelling over the face and pedal edema
Hemodialysis (number of procedures)53Nil10
Length of hospital stay (days)2161231

NVD=Normal vaginal delivery, LSCS=Lower segment caesarean section, IUFD=Intra uterine fetal death, PE=Plasma exchange

Clinical profile of patients suspected of HELLP NVD=Normal vaginal delivery, LSCS=Lower segment caesarean section, IUFD=Intra uterine fetal death, PE=Plasma exchange Liver transaminases (aspartate transaminase and alanine transaminase) were grossly deranged in these patients, whereas they were normal in suspected HUS patients. The details of laboratory profile of all patients are summarized in Table 4.
Table 4

Pre- and post-plasma exchange pattern of laboratory (hematological and renal) profile of suspected HELLP patients

Laboratory profile of suspected HELLP syndrome patients
Case/PE proceduresHematological profileRenal profileOutcome (4 months)


Hemoglobin (g/l)Platelet count (109/L)Lactate dehydrogenase (µkat/L)Bilirubin (mg/dl)Peripheral blood film (% schistocytes)Serum urea (mmol/L)Serum creatinine (µmol/L)Urine output (ml/kg/h)








Pre-PEPost-PEPre-PEPost-PEPre-PEPost-PEPre-PEPost-PEPre-PEPost-PEPre-PEPost-PEPre-PEPost-PEPre-PEPost-PE
Case I (3)848111722066.6223.130.70.34231.0629.06406.64495.0401.2Alive with 88.40 creatinine
Case II (2)78129366320.7923.28148.06Nil44.9841.77426.60397.800.150.19Expired
Case III (5)96636517333.9710.258.42.04264.9721.42362.44134.371.21.2Alive with creatinine 97.24
Case IV (3)112765927940.1023.854.02.49167.8314.64545.43265.2000.6Alive with creatinine 265.20

PE=Plasma exchange

Pre- and post-plasma exchange pattern of laboratory (hematological and renal) profile of suspected HELLP patients PE=Plasma exchange

Response to plasma exchange therapy and outcome of suspected HELLP patients

PE was initiated in all of these patients within 7 days of the onset of illness. Three patients were on alternate-day hemodialysis. Of four patients, three had oliguria and one had normal urine output. After PE therapy, urine output and other renal function parameters [Table 4] improved in the oliguric patients, however, one patient (Case IV) expired due to pulmonary aspiration.

Discussion

Pregnancy is a state of increased prothrombotic activity because of increased concentration of procoagulants, decreased fibrinolytic activity, loss of thrombomodulin, and decreased activity of ADAMTS13 level.[4] Activation of alternate pathway by systemic infection, hemorrhage, and inflammation along with predisposition due to various mutations in complement pathway regulators results in complement dysregulation.[5] This dysregulation or loss of this effective control of complement activation results in signs and symptoms of HUS in pregnancy.[6] Literature supports that pregnancy is a precipitating event for TTP/HUS in women with congenital TTP-HUS who present with the first episode during their first pregnancy associated with the early appearance of signs and symptoms such as severe pallor, oliguria, and renal failure. Four of five patients in our study were primigravida, and all of them presented with low urine output within 1 week of delivery. There was no family history as well as past history of similar illness in these patients. One of them was a multigravida, who developed signs/symptoms of HUS after abortion at 28 weeks most probably due to sepsis following a severe postpartum hemorrhage. The early onset of postpartum HUS has been reported in the age group of 27 ± 6 years,[5] and our patients were in the range of 23–30 years with the early onset of HUS in postpartum period which is comparable to the study by Shrivastava et al. and Wessel et al.[78] Since these patients were referred from community health-care centers to our tertiary care center, due to renal insufficiency in postpartum period, hence HUS was considered as provisional diagnosis. PE therapy was started without delay in these patients without waiting for ADAMTS13 inhibitor and complement-level estimation as these tests are not routinely done in our center, and samples are to be sent to the reference laboratories. The early initiation of PE therapy is also supported by the current ASFA guidelines[1] for TTP-HUS on empirical basis. Since patients went into sepsis due to poor postpartum care so, only 2 of 5 (40%) patients could survive even after extensive PE therapy and alternate hemodialysis despite an early referral. Whereas, in a study by Shrivastava et al.,[7]2 patients of 3 were doing well in their follow-up. Due to high mortality reported with postpartum HUS, it is important for the obstetricians to be aware and consider urgent initiation of PEs in addition to hemodialysis in cases of postpartum/abortion females presenting with acute renal failure and anemia with thrombocytopenia by timely referral or bedside initiation of PE to decrease the mortality associated with the disease. Another complication of pregnancy is HELLP syndrome that presents mostly in the last trimester of pregnancy or in postpartum period in some cases. The exact pathogenesis is not clear, but endothelial dysfunction and inflammatory response may contribute to thrombotic microangiopathy in HELLP. The condition is characterized by signs and symptoms of preeclampsia such as hypertension and proteinuria. All our patients suspected of HELLP had evidence of antenatal hypertension in the last trimester of pregnancy. The coagulation profile and liver functions tests were highly deranged in patients of HELLP syndrome.[9] The definite treatment for HELLP is to terminate the pregnancy by LSCS, but if the condition is not improving even after delivery, PE is considered in these patients as PE removes circulatory protein-bound platelet aggregates and procoagulant factors released from platelets and endothelial cells. Studies have shown increased maternal mortality and very poor neonatal outcome born to a mother with HELLP syndrome[10] as observed in our study with stillbirth in 2 of 4 HELLP patients; however, after PE, three of four patients of HELLP survived in our study which further emphasizes the need of urgent initiation of PE procedures on a daily basis.

Conclusion

Thus, increased morbidity and mortality burden of pregnancy-induced microangiopathies can be decreased through the early detection of clinical signs and symptoms in pregnancy/postpartum and timely initiation of PE therapy along with improvement of maternal and child health-care facilities in peripheral health settings in India.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  8 in total

1.  Maternal mortality and severe maternal morbidity from acute fatty liver of pregnancy in the Netherlands.

Authors:  Ruth R Dekker; Joke M Schutte; Jelle Stekelenburg; Joost J Zwart; Jos van Roosmalen
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2011-03-25       Impact factor: 2.435

Review 2.  Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue.

Authors:  Joseph Schwartz; Anand Padmanabhan; Nicole Aqui; Rasheed A Balogun; Laura Connelly-Smith; Meghan Delaney; Nancy M Dunbar; Volker Witt; Yanyun Wu; Beth H Shaz
Journal:  J Clin Apher       Date:  2016-06       Impact factor: 2.821

Review 3.  Endothelial cells and thrombotic microangiopathy.

Authors:  David Motto
Journal:  Semin Nephrol       Date:  2012-03       Impact factor: 5.299

4.  Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations.

Authors:  Fadi Fakhouri; Lubka Roumenina; François Provot; Marion Sallée; Sophie Caillard; Lionel Couzi; Marie Essig; David Ribes; Marie-Agnès Dragon-Durey; Frank Bridoux; Eric Rondeau; Veronique Frémeaux-Bacchi
Journal:  J Am Soc Nephrol       Date:  2010-03-04       Impact factor: 10.121

5.  Early diagnosis and management of postpartum hemolytic uremic syndrome with plasma exchange.

Authors:  Manisha Shrivastava; Gopesh Modi; Rakesh Kumar Singh; Seema Navaid
Journal:  Transfus Apher Sci       Date:  2011-05-06       Impact factor: 1.764

6.  Incidence of obstetrical thrombotic thrombocytopenic purpura in a retrospective study within thrombocytopenic pregnant women. A difficult diagnosis and a treatable disease.

Authors:  Yahsou Delmas; Sébastien Helou; Pierre Chabanier; Anne Ryman; Fanny Pelluard; Dominique Carles; Pierre Boisseau; Agnès Veyradier; Jacques Horovitz; Paul Coppo; Christian Combe
Journal:  BMC Pregnancy Childbirth       Date:  2015-06-17       Impact factor: 3.007

Review 7.  Pregnancy outcomes in patients with acute kidney injury during pregnancy: a systematic review and meta-analysis.

Authors:  Youxia Liu; Xinxin Ma; Jie Zheng; Xiangchun Liu; Tiekun Yan
Journal:  BMC Pregnancy Childbirth       Date:  2017-07-18       Impact factor: 3.007

Review 8.  Acute Kidney Injury in Pregnancy: The Changing Landscape for the 21st Century.

Authors:  Swati Rao; Belinda Jim
Journal:  Kidney Int Rep       Date:  2018-02-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.